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Background: There is uncertainty on the benefit of adjuvant chemotherapy in patients with stage II colorectal
cancers. The aim of this study is to investigate the combined role of clinical, pathological and molecular parameters
to identify those stage II patients who better benefit from adjuvant therapy.
Methods: We examined 120 stage II colon cancer patients. Of these, 60 patients received adjuvant 5-FU
chemotherapy after surgery and the other 60 did not receive therapy. Immunohistochemical (IHC) analyses were
performed to evaluate the expressions of Thymidylate synthetase (TYMS), TP53 (p53), β-catenin (CTNNB1) and CD8.
For TYMS, its mRNA expression levels were also investigated by real time qRT-PCR. The entire case study was
characterized by the presence of a defect in the MMR (mismatch repair) system, the presence of the CpG island
methylator phenotype (CIMP or CIMP-High) and for the V600E mutation in the BRAF gene. At the histo-pathological
level, the depth of tumour invasion, lymphovascular invasion, invasion of large veins, host lymphocytic response
and tumour border configuration were recorded.
Results: The presence of the V600E mutation in the BRAF gene was a poor prognostic factor for disease free and
overall survival (DFS; hazard ratio [HR], 2.57; 95% CI: 1.03 -6.37; p = 0.04 and OS; HR, 3.68; 95% CI: 1.43-9.47; p < 0.01
respectively), independently of 5-FU treatment. Adjuvant therapy significantly improved survival in patients with
high TYMS levels (p = 0.04), while patients with low TYMS had a better outcome if treated by surgery alone (DFS;
HR, 6.07; 95% CI, 0.82 to 44.89; p = 0.04). In patients with a defect in the MMR system (dMMR), 5-FU therapy was
associated to reduced survival (DFS; HR, 37.98; 95% CI, 1.04 to 1381.31; p = 0.04), while it was beneficial for CIMP-
High associated tumours (DFS; HR, 0.17; 95% CI, 0.02 to 1.13; p = 0.05).
Conclusions: Patients’ characterization according to MMR status, CIMP phenotype and TYMS mRNA expression may
provide a more tailored approach for adjuvant therapy in stage II colon cancer.
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Colorectal cancer (CRC) is the third most common
tumour in men and the second in women worldwide
and it is the fourth most common cause of death from
cancer [1].
Colorectal cancer has usually been viewed as a homoge-
neous entity rather than a complex heterogeneous disease* Correspondence: sbonin@units.it
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reproduction in any medium, provided the ordeveloping through multiple genetic and epigenetic abnor-
malities, such as defective DNA mismatch repair (dMMR)
and the CpG island methylator phenotype (CIMP) [2,3].
The functional consequence of failure of the MMR system
is a high-frequency of microsatellite instability (MSI-H), the
condition in which cancers show an increased rate of repli-
cation errors in the highly repetitive short DNA sequences
called microsatellites [4]. CpG island methylator phenotype
(CIMP or CIMP-High) comprises a subset of colorectal car-
cinoma characterized by extensive hypermethylation of
multiple promoter CpG island loci and peculiar clinico-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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findings have identified the CIMP-Low cancer subtype,
which appears to be a distinct biological subtype of colorec-
tal cancer with respect to CIMP-High and which is
characterized by less extensive CIMP-specific promoter
methylation [5,6].
Adjuvant chemotherapy, mostly based on the use of the
antimetabolite 5-Fluorouracil (5-FU), is mainly provided for
patients with stage III CRCs, whereas evidence on the use-
fulness of adjuvant therapy in stage II CRC patients is con-
troversial [7]. Current treatment protocols recommend
adjuvant treatment only to stage II patients with high-risk
pathological features (e.g. T4 stage, bowel perforation or
clinical bowel obstruction, inadequate lymph node sam-
pling, poorly differentiated histology) [8,9]. As to histo-
pathological characteristics, other high-risk features such as
lympho-vascular invasion [10,11], absence of tumour in-
flammatory response [12,13] and presence of tumour bud-
ding [14] are also suggested as indicating a higher risk of
recurrence and hence a worse prognosis.
The histo-pathological approach is paramount in can-
cer classification, however for most patients with stage II
disease who are classified as standard risk, there are no
additional markers to refine risk assessment or to predict
adjuvant chemotherapy benefit. This limitation could be
overcome by the use of molecular biomarkers in
addition to pathological classification, aiming at a more
personalized approach in cancer treatment. Molecular
markers may have prognostic or predictive value. Prog-
nostic biomarkers provide information on the clinical
outcome at the time of diagnosis, independently of ther-
apy, whereas predictive biomarkers provide information
about the likelihood of response to a given therapeutic
modality based on marker status, and therefore could be
used to guide treatment [15]. In colorectal cancer, sev-
eral potential molecular predictors of recurrence risk
and chemotherapy benefit have been investigated [16].
Previous reports suggested that patients with a defective
DNA mismatch repair system (dMMR) show improved
prognosis over those with proficient mismatch repair
(pMMR) [17] and they do not receive benefit from 5-FU
based adjuvant therapy [18,19]. Moreover, recent
findings highlighted that benefit to 5-FU based adjuvant
therapy in dMMR patients was restricted to suspected
germline (ie Lynch syndrome) vs sporadic tumours, es-
pecially in stage III cancers [20].
Unlike MMR studies, reports focusing on the relation-
ship between CIMP status and survival have yielded
contradictory results. Some authors have suggested that
patients with CIMP colorectal tumours do not benefit
from 5-FU-based adjuvant chemotherapy [21], while
others have observed an independent association of CIMP
status to lower specific cancer mortality [22]. Many other
single molecular markers have been investigated asprognostic or predictive in CRC [23]. Among them, the
most studied is Thymidylate synthetase (TYMS), which
has been extensively studied as a predictive factor for
response to adjuvant fluoropyrimidine chemotherapy.
TYMS is the key enzyme for the cellular production of the
thymidine monophosphate (dTMP), which is considered
the main target of the 5-FU. Some studies reported a posi-
tive relationship between TYMS expression and survival
[24], while others showed a negative relationship [25] or
no correlation [26,27].
The identification of prognostic and predictive markers
of therapy efficacy for stage II CRC is pressing because the
rate of recurrence for patients with stage II colon carcin-
oma was reported to be around 15% [28] and stage II
cancers represent 30-40% of all resected colorectal
cancers. This percentage is going to increase because of
the screening programmes [29]. This study aims to deepen
investigation on the possibility of combining classical
histo-pathological features with molecular alterations (at
the genomic, transcriptomic and epigenomic level) for a
more tailored adjuvant therapy in stage II colorectal can-
cer. For our study we selected as candidate molecular
markers the colorectal cancer classifiers MMR system and
CIMP, as well as the following single molecular markers:
TP53 (p53), β-catenin (CTNNB1), BRAF c.1799 T >A
(V600E) mutation and TYMS. The first three markers
were chosen because they are involved in CRC tumorigen-
esis [30], whereas TYMS was analysed because it could be
used to identify a subgroup of stage II colon cancer
patients who better benefit from the use of adjuvant
chemotherapy, as we pointed out in a previous study [31].
Among the pathological factors we considered the
following ones, which have been recognized as prognos-
tic in the assessment of the risk of recurrence in CRCs:
the depth of tumour invasion [32], the lympho-vascular
invasion and the invasion of large veins [10,11], the pres-
ence of a tumour inflammatory response [12,13] and the
tumour border configuration [14].
Methods
To identify prognosis-related and predictive markers of
therapy efficacy in CRC, a cohort of 120 patients
diagnosed with exclusively colon cancer of stage II and
treated with surgery alone or surgery plus 5-FU based
adjuvant chemotherapy were included in our survey. All
molecular analyses were performed on formalin-fixed
paraffin-embedded tissues (FFPE) specimens to directly
compare experimental results with the patients’ clinical
data and follow up.
Patients
FFPE cancer tissues were obtained from 120 patients
whose diagnosis was primary colon adenocarcinoma of
stage II. These patients were treated with surgery alone
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fluorouracil 370–420 mg/m2 plus leucovorin 20–
200 mg/m2 on day 1–5, repeated every 4–5 weeks for 6 -
months). Patients were selected among over 1000
patients, diagnosed with colorectal cancer and treated at
the Trieste University Hospital. Of these, only those
patients with exclusively colonic tumours of stage II and
for whom clinical follow-up and archival material was
available were included in the study. Another criterion
in selection was homogeneity in therapeutic treatment.
In particular, none of the patients received any
anticancer treatment prior to surgery and at the time of
the first diagnosis they did not present with any other
cancers. Patients receiving 5-FU therapy after surgery
and those treated with surgery alone were matched
according to sex and age. From each patient, normal dis-
tal colon tissue was also recovered. Patients were
followed through the population-based Friuli–Venezia
Giulia Cancer Registry from diagnosis of cancer to the
appearance of the first recurrence and to death or until
15 December 2010, whichever came first. The study was
submitted for evaluation to the Ethical Committee of the
University of Trieste, who approved it.Pathologic examination
Pathologic examinations (on hematoxylin-eosin slides)
were performed independently by two pathologists (G.S
and R.B.) on the entire case study to confirm tumour
grade and histotype components and to evaluate the
following factors: depth of tumour invasion, lympho-
vascular invasion, large veins invasion, tumour infiltrating
lymphocytes, Chron’s like reaction and the configuration
of the tumour border. Evaluations of such parameters
were quoted as in reference literature [33]. In particular, in
the evaluation of tumour infiltrating lymphocytes,
tumours were considered infiltrated if five or more intra-
tumour lymphocytes per high-power field were detected
(92% of concordance of identification, Kappa value of
0.79). Lympho-vascular invasion, large veins invasion and
Chron’s like reaction were dichotomized as “no” or “yes”
according to their absence or evident presence (85%, 87%
and 88% of identification concordance for the two
pathologists for the three parameters, with corresponding
kappa values of 0.64, 0.67 and 0.71 respectively). Finally,
the tumour border configuration was defined as “pushing”
when tumours were smooth and rounded and they
appeared to push into adjacent tissues, while it was
defined as “infiltrative” when an irregular leading edge of
cells infiltrated normal tissues with small groups of
separated cells (96% of concordance; kappa value = 0.89).
Discrepancies in evaluations were solved by simultaneous
re-examination of the slides by both investigators using a
double-headed microscope.DNA isolation and CpG island methylation status analysis
DNA was extracted from FFPE tissues of each patient’s
tumour after mechanical microdissection, as described
elsewhere [34]. After DNA extraction, sodium bisulfite
conversion of the DNA was performed using a homemade
method as previously described [34]. A tumour was
defined CIMP-High if it showed methylation in at least
three of the five methylation markers (CACNA1G,
IGF2, NEUROG1, RUNX3, and SOCS1), suggested by
Weisenberger et al. [35]. CIMP-Low tumours were defined
as tumours with 1/5 and 2/5 methylated promoters and
CIMP-0 were those cancers with no methylated pro-
moters. DNA methylation in the CpG islands of these five
CIMP markers was determined by Methylation Specific
PCR (MSP) as already reported [36,37]. Detection of the
MSP reactions was done by non-denaturing poly-
acrylamide electrophoresis, stained with ethidium brom-
ide. Two assays were performed for each locus and a
CpG-island was defined as methylated when both assays
showed amplification. When one of two assays showed no
amplification, a third assay was performed to ascertain
whether that locus was methylated or not.
BRAF c.1799 T > A mutation analysis (V600E)
BRAF c.1799 T >A mutation was searched by semi-nested
PCR using the following primers: Forward outer primer:
50-CTTGCTCTGATAGGAAAATGAGA-30; Forward in-
ner primer: 50TGTTTTCCTTTACTTACTACAC-30; Re-
verse primer: 50-TCTTACCATCCACAAAATGGA-30.
Amplicons span exon 15, codon 600, with a final inner
amplicon length of 174 bp. PCR was performed under
the following conditions: initial denaturation step of
95°C for 30; 40 cycles of 95°C for 30 s; annealing at 51°C
for 30 s; 72°C for 30 s; and a final elongation step of
72°C for 50. One microliter of the first PCR reaction
product was used as a template in the second PCR
round. Thermal profile of the latter was the same as the
first, despite the final number of cycles (30 cycles). The
inner PCR products were first analyzed by 2.5% agarose
gel electrophoresis, then purified using the QIAquick
PCR purification kit (Qiagen) and submitted to direct
sequencing. Standard dideoxy sequencing reaction and
sequencing run were performed at the BMR-genomics
sequencing core facility (http://www.bmr-genomics.it/;
Padua, Italy).
RNA isolation and TYMS analysis
For each patient, total RNA was extracted from FFPE
specimens of primary colon adenocarcinomas after
mechanical microdissection, as described elsewhere [34]
and reverse-transcribed into cDNA after DNase treat-
ment as previously reported [38]. TYMS mRNA expres-
sion levels were analysed by means of real time qPCR.
Amplification was performed using a MastercyclerW ep
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normalized as already reported [31].Tissue microarray (TMA) construction and
immunohistochemistry
TMA blocks were prepared with inclusion of tumour and
matched normal tissues, chosen by a pathologist. Areas
without haemorrhage, necrosis, poor fixation or tissue
processing artefacts were selected and punched with
1.5 mm sized cores. For specimens histologically non-
homogeneous we extracted more tissue cores, representa-
tive of the different areas. For those cases an average of
the count was used for the IHC analysis. The TMA blocks
were cut in 4 μm sections for immunohistochemical
staining. Immunostaining for each antigen was conducted
using the avidin-biotin peroxidase complex technique
(Vectastain Universal Elite ABC Kit, Vector Laboratories),
following the manufacturer’s instructions. The antibodies
TYMS (clone TS106, Millipore; diluted 1:50), MLH1
(clone G168-15, BD Pharmingen; diluted 1:25), MSH2
(clone G219-1129, BD Pharmingen; diluted 1:100), TP53
(clone DO-7, Ventana Medical Systems; pre-diluted), β-
catenin (CTNNB1) (clone 14, Cell Marque; pre-diluted)
and CD8 (clone SP57, Ventana Medical System; pre-
diluted) were used. The IHC results were evaluated by two
pathologists independently. In detail, for TYMS tumours
were classified as “low” or “high” expression groups as
already reported [26]. Tumours showing loss of nuclear
MLH1 or MSH2 expression were classified as dMMR (i.e.
with a defective MMR system), whereas the other tumours
were defined as pMMR (i.e. with a proficient MMR sys-
tem) as already suggested [19]. In 29 patients from the
case study, MSI determination by microsatellite analysis
[39] was also performed to check the equivalence of this
method with the determination of the MMR system status
through the immunohistochemical evaluation of MLH1
and MSH2.
TP53 immunoreactivity was dichotomised into positive
and negative, based on staining of malignant nuclei, with
a threshold of 10% [26]. For CTNNB1 (ß-catenin) evalu-
ation, cytoplasmic, nuclear and membrane expressions
were separately recorded as no or weak expression,
moderate expression, or strong expression. Positivity in
each compartment (cytoplasm, nucleus and membrane)
was then defined as moderate/strong expression in that
compartment as already described [40]. We also
calculated the grades of activation of CTNNB1, as previ-
ously reported [40]. Immunoreactivity for CD8 was done
by assessing the percentage of immunoreactive
leukocytes in the tumoral area in a high magnification
field, over the total number of leukocytes identified in
the same field. The observations coming from three
magnification fields were averaged.Statistical analysis
Associations between clinical-pathological data and cat-
egories of markers were tested for significance using the
chi-square test (or Fisher’s exact test depending on the
number of samples) for categorical variables. For continu-
ous variables the parametric Student’s t-test or the one-
way ANOVA test was used. Differences in the clinical,
pathological and molecular characteristics between the
group of patients treated with surgery alone and those
submitted to adjuvant chemotherapy were evaluated with
statistical tests for paired variables. The level of agreement
between estimators was assessed using the Cohen’s kappa
statistics. Real time qRT-PCR normalized values for
TYMS were dichotomized for subsequent survival analysis
with respect to the median value of expression. Tumours
with gene expression levels lower or higher than the me-
dian value were classified as low or high status of expres-
sion, respectively. The primary end-point of the study was
disease free survival (DFS), defined as the time from initial
diagnosis to the first recurrence diagnosis. Overall survival
(OS), which was defined as the time from surgery to colon
cancer specific death, was the secondary end-point. In de-
tail, in this study disease free patients were: 1) those who
were alive and without recurrences at the end of the
follow-up (15/12/2010); 2) those who died of causes not
related to colon cancer and without recurrences during
the follow-up (end of follow-up is the death date); 3) those
who were alive and without recurrences, but emigrated
(end of follow-up is the emigration date). To estimate the
joint effects of the analysed covariates on patients’ survival,
the data were analysed by fitting the Cox proportional
hazard regression model. Cox proportional hazard analysis
included: age at diagnosis, tumour location, tumour grade
and the complete set of the pathological and molecular
markers analysed. The log-rank test was used to check the
dependence of patients’ survival on single variables or on
combinations of variables. All p-values are two-sided with
values <0.05 regarded as statistically significant. Although
not really significant, P-values between 0.05 and 0.07 were
considered “borderline”, as already done by other authors
[41] since they could give some indication on the trend.
Statistical analyses were performed with the Stata/SE
9.2 package (Stata, College Station, TX).
Results
Description of patients’ cohort according to clinical,
pathological and molecular features
The study population comprised 120 patients with stage
II colon cancer who were divided into two subgroups
according to the treatment after surgery. Patients
belonging to the two subgroups were matched for sex
and age. The median duration of overall follow up was
9.4 years (25th-75th percentile = 3.3-11.8 yrs). Clinical-
pathological and molecular reports of the patients are
Table 1 Clinical, pathological and molecular characteristics of colon cancer patients in the two cohorts of treatment
Frequency N (%)
Surgery alone (n = 60; 50%) 5-FU therapy (n = 60; 50%) p
Clinical-pathological features Age, mean (SD), years 67.4 (10.44) 67.7 (10.8) 0.9
Sex Male 28 (47) 29 (48) 0.3
Female 32 (53) 31 (52)
Tumour location1 Proximal 21 (35) 25 (42) 0.4
Distal 39 (65) 35 (58)
Tumour grade G1 8 (13) 8 (13) 0.5
G2 51 (85) 49 (82)
G3 1 (2) 3 (5)
Depth of tumour invasion pT3 53 (88) 53 (88) 1.0
pT4 7 (12) 7 (12)
Lymphovascular invasion No 39 (65) 37 (62) 0.8
Yes 21 (35) 22 (38)
Large veins invasion No 51 (85) 47 (78) 0.3
Yes 9 (15) 13 (22)
Tumour infiltrating lymphocytes No 53 (88) 48 (80) 0.2
Yes 7 (12) 12 (20)
Chron’s like reaction No 31 (52) 27 (45) 0.4
Yes 29 (48) 33 (55)
Tumour border configuration Pushing 56 (93) 51 (85) 0.2
Infiltrating 4 (7) 9 (15)
Molecular parameters MMR system dMMR 8 (13) 10 (17) 0.6
pMMR 52 (87) 50 (83)
CIMP CIMP-High 8 (13) 14 (23) 0.3
CIMP-Low 18 (30) 18 (30)
CIMP-0 34 (57) 28 (47)
TYMS mRNA expression High level 24 (40) 33 (55) 0.1
Low level 36 (60) 27 (45)
TYMS protein expression (IHC) High 30 (50) 28 (47) 0.7
Low 30 (50) 32 (53)
TP53 Positive 24 (40) 22 (37) 0.7
Negative 36 (60) 38 (63)
CTNNB12 Cytoplasmic localization Positive 41 (68) 41 (69) 0.8
Negative 19 (32) 18 (31)
CTNNB12 Nuclear localization Positive 18 (30) 26 (44) 0.1
Negative 42 (70) 33 (56)
CTNNB12 Membrane localization Positive 27 (45) 19 (32) 0.1
Negative 33 (55) 40 (68)
BRAF c.1799 T > A Wild type 51 (85) 52 (87) 1.0
Mutated 9 (15) 8 (13)
1: Proximal colon includes cecum to transverse colon and distal colon includes splenic flexure to sigmoid colon.
2: One of the 60 cases treated with 5-FU was excluded from the analysis because of poor staining.
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treated with surgery alone and of those treated with sur-
gery plus 5-FU adjuvant therapy are similar.
Immunohistochemical analysis showed that the percent-
age of intra-tumoral cytotoxic T lymphocytes (CD8+) was
higher in cases classified as having tumour infiltrating
lymphocyes and indicated that these infiltrating lymphocyes
were mostly cytotoxic T lymphocytes (CD8+) (p < 0.01).
The presence of tumour infiltrating lymphocytes was
associated with the presence of a Chron’s like reaction in
the border of the tumour (p < 0.01). For this reason these
two features are analyzed together and referred to as
“tumour inflammatory response” hereinafter.
Molecular marker analysis and relationship with clinical
and pathological features
Fifteen per cent of tumours were classified as dMMR.
Deficient MMR tumours developed at higher frequencies
at proximal sites than pMMR ones (p < 0.01) and tended
to be less differentiated (p < 0.01). The presence of a
tumour inflammatory response was also more frequent
in patients with dMMR tumours (p = 0.03) (Table 2).Table 2 Clinical and molecular characteristics of colon cancer










1Significant or borderline p values are bolded.Eighteen per cent of tumours were classified as CIMP-
High, 30% were defined as CIMP-Low, while CIMP-0
comprised 52% of all tumours. CIMP-High and CIMP-0
tumours were more common in women, while CIMP-
low were more common in men (p = 0.02; Table 2).
CIMP-High phenotype was significantly associated with
poor histological grade (p = 0.04) and dMMR (p < 0.01).
In detail, 50% of CIMP-High tumours showed a defect
in the MMR system, compared with only 5% of CIMP-
Low and 8% of CIMP-0 ones. Moreover, tumour location
bowel sub-site (from cecum to descending colon) was
significantly linearly associated with dMMR (p < 0.01),
but not with CIMP-High (p < 0.2). In detail, the frequen-
cies of dMMR tumours were significantly decreasing
from cecum to sigma.
Thymidylate synthetase expression was analysed both
at the mRNA and at the protein level (by IHC). No cor-
relation was observed between TYMS expression and
any clinical-pathological variable, with the exception of
tumour location, with higher TYMS mRNA expression
in proximal tumours (p = 0.02). Interestingly, no correl-






pMMR dMMR p CIMP-0 CIMP-L CIMP+ p
102 (85) 18 (15) 62 (52) 36 (30) 22 (18)
Male 50 (59) 7 (39) 0.4 24 (39) 24 (67) 9 (41) 0.02
Female 52 (41) 11(61) 38 (61) 12 (33) 13 (59)
Proximal 34 (33) 12 (67) <0.01 25 (40) 9 (25) 12 (54) 0.07
Distal 68 (67) 6 (33) 37 (60) 27 (75) 10 (46)
G1 13 (13) 3 (17) <0.01 8 (13) 6 (17) 2 (9) 0.04
G2 88 (86) 12 (67) 54 (87) 29 (81) 17 (77)
G3 1 (1) 3 (17) 0 (0) 1 (2) 3 (14)
No 51 (50) 4 (22) 0.03 26 (42) 20 (55) 9 (41) 0.4
Yes 51 (50) 14 (78) 36 (58) 16 (45) 13 (59)
High 44 (43) 13 (72) 0.02 22 (35) 19 (53) 16 (73) <0.01
Low 58 (57) 5 (28) 40 (65) 17 (47) 6 (27)
High 52 (51) 6 (33) 0.2 30 (48) 16 (44) 12 (55) 0.2
Low 50 (49) 12 (67) 32 (52) 20 (56) 10 (45)
Positive 44 (43) 2 (11) <0.01 27 (44) 9 (25) 10 (45) 0.1
35 (56) 27 (75) 12 (55)Negative 58 (57) 16 (89)
1 34 (33) 11 (66) 0.02 19 (31) 19 (53) 7 (32) 0.08
2 54 (53) 3 (17) 33 (54) 15 (42) 9 (41)
3 14 (14) 3 (17) 9 (15) 2 (5) 6 (27)
Wild 91 (89) 13 (72) 0.05 54 (87) 32 (89) 18 (82) 0.7
Mutated 11 (11) 5 (28) 8 (13) 4 (11) 4 (18)
Figure 1 Survival of the study population as a whole. Kaplan-
Meier curves showing disease free survival in patients treated with
surgery alone or with surgery plus adjuvant 5-FU based therapy.
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CTNNB1expression, one of the 120 cases was excluded
from the analysis because of poor staining quality. Over-
all, 69% of tumours showed cytoplasmic positivity, 37%
exhibited nuclear positivity and 39% displayed mem-
brane positivity. Different types of positivity could be
observed in the same sample. CTNNB1grades of activa-
tion were calculated as previously reported [40]. A
strong relationship was found between CTNNB1activation
degrees and CTNNB1expression according to locali-
zation, with nuclear/cytoplasmic expressions being more
associated with higher degrees (p < 0.01). For this reason,
to reduce the number of variables, in place of cellular
localizations, the degrees of activation of CTNNB1 are
considered in the analysis hereinafter.
TP53 showed nuclear immunoreactivity in 38% of the
cases and BRAF c.1799 T >A mutation was detected in
13% of tumours. All these molecular parameters were un-
related with the clinical and pathological characteristics
that were considered.
Molecular correlates
Complex cellular events in CRC include CIMP and MSI.
In our study we used immunohistochemistry of MLH1
and MSH2 as a surrogate marker of MSI, after demon-
strating that immunohistochemical assessment of MLH1
or MSH2 corresponds to MSI testing. Concordance for
the identification of a defect in the MMR system between
IHC and MSI assessment by PCR was of 93% (Kappa
value = 0.76; p < 0.01). Molecular correlations with CIMP
and MMR are reported in Table 2. Thymidylate synthetase
mRNA expression levels were significantly associated with
the MMR system status and the CIMP status. In detail,
72% of dMMR patients expressed higher levels of the
TYMS gene (p = 0.02) and 73% of patients with a CIMP-
High status had a high TYMS status (p < 0.01) (Table 2).
Conversely TYMS protein expression levels (by IHC) were
found to be unrelated to MMR and CIMP (Table 2). TP53
positive staining was related to MMR system status:
tumours lacking TP53 nuclear positivity were mostly
dMMR, while nuclear positivity for p53 was related to
pMMR (p < 0.01). No relationship was found between
TP53 nuclear immunostaining and CIMP status (p = 0.1)
(Table 2). Tumours with a dMMR were characterized by
lower degrees of activation of CTNNB1 (p = 0.02) and the
presence of c.1799 T >A mutation in the BRAF gene (p =
0.05) (Table 2).
Survival analysis
At the end of the follow-up 26 patients died for colon
cancer progression, with a median overall survival of 3.2 -
years (25th-75th percentile = 1.9-6.8 yrs) for patients who
only received surgical therapy and 2.9 years (25th-75th
percentile =2.1-3.3 yrs) for those treated with 5-FU. Indetail, specific cancer death was recorded for 14 patients
who did not receive adjuvant treatment (23%) and for 12
patients (20%) who were treated with adjuvant chemo-
therapy. The median DFS was of 1.9 years (25th-75th per-
centile = 0.8-3.7 yrs) for the 14 patients who did not
receive adjuvant treatment and 1.5 years (25th-75th per-
centile = 0.7-2.3 yrs) for the others. Considering the en-
tire case study, no benefit from adjuvant treatment was
detected (Figure 1).
Cox proportional hazard model, including as covariates
all clinical, pathological and molecular variables and 5-FU
treatment identified BRAF c.1799 T >A mutation as the
most important predictor of survival (Table 3). This means
that the presence of the mutation c.1799 T >A in the
BRAF gene is a poor prognostic factor, independently of
5-FU treatment. The presence of CD8+ lymphocytes infil-
trating the tumour, the presence of a lymphocytic reaction
at the margin of the tumour as well as the presence of a
tumour without an infiltrating border seem to be good
prognostic factors, but these data do not reach statistical
significance (Table 3).
The cohort of patients was then divided into two
groups with respect to the adjuvant treatment, and the
Cox proportional hazard regression analysis was
repeated separately for the two groups (Table 4). For
those patients treated with surgery alone, an independ-
ent influence on cancer-progression was detected for the
TYMS mRNA expression (p = 0.04; Table 4), while for
those patients submitted to adjuvant 5-FU treatment
after surgery, the MMR and the CIMP were the most
important predictors of survival (p = 0.04 and p = 0.05
respectively; Table 4). Similar results were obtained for
the overall survival analysis.
In detail, a low TYMS expression seems to have a pro-
tective effect in chemotherapy untreated patients, while in
the group of patients who received adjuvant chemotherapy
Table 3 Results of Cox multivariate analysis in the entire patients’ cohort1
Disease free survival Overall survival
HR (p) HR (p)
Clinical-pathological features Age 1.93 (0.2) 1.71 (0.3)
Sex 0.70 (0.5) 0.81 (0.7)
Tumour location 1.50 (0.4) 1.85 (0.2)
Tumour grade 1.29 (0.7) 0.81 (0.7)
5-FU treatment 1.23 (0.7) 1.12 (0.8)
Depth of tumour invasion 0.94 (0.9) 1.27 (0.7)
Lymphovascular invasion 0.70 (0.4) 0.61 (0.3)
Large veins invasion 1.08 (0.9) 0.88 (0.8)
Tumour inflammatory response 0.39 (0.06) 0.40 (0.09)
Tumour border configuration 2.77 (0.06) 2.91 (0.1)
Molecular parameters MMR system 1.54 (0.6) 0.97 (1.0)
CIMP 0.58 (0.2) 0.60 (0.3)
TS by mRNA 1.15 (0.7) 1.31 (0.5)
TS by IHC 0.88 (0.8) 0.64 (0.4)
TP53 0.62 (0.2) 0.37 (0.08)
CTNNB1activation grades 0.80 (0.4) 0.90 (0.8)
BRAF c.1799 T > A 2.57 (0.04) 3.68 (<0.01)
1Significant or borderline p values are bolded.
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http://www.biomedcentral.com/1471-230X/13/36after surgery, the presence of a defect in the MMR system
(dMMR) appears pejorative for patients’ survival. In
treated patients, conversely, the presence of the CpG is-
land methylator phenotype (CIMP-High) was a protective
















BRAF c.1799 T > A
1Results of Cox multivariate analysis here reported are referred to DFS (disease freeTYMS mRNA levels, MMR and CIMP statuses have
been found as the only markers associated with patients’
survival after their stratification according to treatment,
so we hypothesized that these markers could have a pre-
dictive role on treatment efficacy. A harmful effect fromts belonging to the two groups of treatment1
Surgery alone 5-Fu therapy
HR (p) HR (p)
0.66 (0.6) 3.43 (0.2)
0.99 (1.0) 1.34 (0.8)
2.09 (0.5) 1.36 (0.7)
0.71 (0.7) 1.99 (0.7)
5.22 (0.2) 1.26 (0.9)
0.50 (0.4) 0.27 (0.2)
2.14 (0.4) 0.40 (0.3)
1.30 (0.6) 0.53 (0.1)
4.91 (0.2) 2.18 (0.6)
0.15 (0.2) 37.85 (0.04)
0.67 (0.6) 0.17 (0.05)
6.08 (0.04) 0.54 (0.2)
0.35 (0.1) 2.03 (0.4)
0.71 (0.7) 0.63 (0.6)
0.35 (0.1) 1.60 (0.5)
2.67 (0.3) 2.99 (0.3)
survival). Significant or borderline p values are bolded.
Figure 3 Disease free survival by MMR and CIMP in patients
treated with 5-FU. Survival curves related to Cox proportional
hazard regression with respect to DNA mismatch repair (MMR)
status in a) and CpG island methylator phenotype (CIMP) in b).
dMMR, deficient DNA mismatch repair; pMMR, proficient DNA
mismatch repair; CIMP-High, presence of CpG island methylator
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http://www.biomedcentral.com/1471-230X/13/365-FU treatment was observed in patients with low
TYMS levels (p = 0.05; Figure 4), whereas in patients
with high TYMS levels a benefit from 5-FU treatment
was found (p = 0.04; Figure 4). No effect from 5-FU ther-
apy was found for patients CIMP-0, CIMP-Low or for
those MMR proficient (p = 0.7, p = 0.9 and p = 0.7 re-
spectively). In the latter group, however, high TYMS ex-
pression was linked to better outcome after therapy (p =
0.03; Figure 5). These data were also consistent with OS
analysis. Of note, in the group of patients showing a low
TYMS level, at five years of follow up, overall survival
was 91% for patients being treated with surgery alone
versus 67% of those treated with 5-FU. The opposite re-
sult was seen for patients with high TYMS levels: at five
years of follow up, overall survival was 70% for patients
being treated with surgery alone versus 90% of those also
treated with 5-FU.
Evaluation of 5-FU therapy efficacy in dMMR and
CIMP-High tumours was not assessed because of the
low number of recurrent patients in these groups (4
cases only for both markers).
Discussion
Adjuvant therapy in patients with stage II colon cancer
is a subject of controversy because of the small gains in
survival for this group of patients [7]. Apparently, that
was confirmed by our results, showing that the addition
of adjuvant treatment to patients with node-negative
cancers did not improve DFS and OS (Figure 1). Uncer-
tainty on the benefit of adjuvant chemotherapy in
patients with stage II colon cancers is due to the fact
that we don’t know which of the stage II patients are at
high risk of recurrence and which may benefit fromFigure 2 Disease free survival by TYMS mRNA expression in
patients treated with surgery alone. Survival curves related to Cox
proportional hazard regression with respect to TYMS mRNA
expression levels in the subgroups of low TYMS (TYMS expression
lower than the median value) or high TYMS (TYMS expression
higher than the median value).
phenotype; CIMP-Low, presence of low levels of methylation;
CIMP-0, absence of CpG island methylator phenotype.chemotherapy [16]. To deepen investigation on these
aspects, in the current study a combination of patho-
logical factors and molecular markers was assessed in
120 cases of stage II colon cancer independently of 5-FU
treatment.
Considering the entire case study, we found that
patients showing c.1799 T > A mutation in the BRAF
gene showed a worse prognosis, independently of 5-FU
treatment, as already reported [42,43]. In addition, even
though non statistically significant, patients having
tumours with a pushing border, or showing a tumour in-
flammatory response, were associated with better sur-
vival. The first finding could be explained by the fact
that an infiltrating tumour margin is strongly associated
with the presence of tumour budding [44], which has
been shown to have independent negative prognostic
Figure 4 Disease free survival by 5-FU treatment according to TYMS expression. Kaplan-Meier survival curves showing disease free survival
in patients with low-TYMS-expressing tumours in a) and in patients with high-TYMS-expressing tumours in b), with respect to treatment with
surgery alone versus surgery followed by adjuvant 5-FU-based chemotherapy.
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the reported good prognostic value of generalized in-
flammatory cell infiltrate in colorectal cancers of stage II
patients [45,46] and may be explained by a tumour-
related immune response.
Interestingly the adverse effect of BRAF mutation on
patients’ outcome appeared to be independent from CIMP
phenotype, since in our case study we could not find an
association between these two parameters, contrarily to
other reports [2,3].
After splitting the group of patients according to treat-
ment, we found a differential effect of 5-FU-based adju-
vant therapy according to thymidylate synthetase (TYMS)
mRNA levels, the presence of a defect in the MMR system
(dMMR) and the presence of the CpG island methylatorFigure 5 Disease free survival by 5-FU treatment in pMMR and
high TYMS. Kaplan-Meier survival curves showing disease free
survival in patients with pMMR and high-TYMS-expressing tumours
with respect to treatment with surgery alone versus surgery
followed by adjuvant 5-FU-based chemotherapy.phenotype, suggesting that these are important parameters
for therapy decision. In patients treated with surgery
alone, a high TYMS expression was inversely correlated
with survival, as previously reported [24,47]. On the con-
trary, an improved clinical outcome was seen for patients
submitted to 5-FU therapy and having a high TYMS ex-
pression. Controversial results have been reported on the
relationship between TS and 5-FU treatment [24-27,31].
Such contradictory results may be related to differences in
patient cohorts and methodological inconsistencies. In
particular, our results showed that TYMS levels measured
by real time qRT-PCR did not correlate with the
corresponding protein levels measured by IHC and the ef-
fect on the outcome was evident for TYMS only when
evaluated at the mRNA level.
Consistent with other studies [19,48], our data suggest a
favourable prognosis in patients with dMMR tumours if
untreated with adjuvant therapy (HR, 0.15; p = 0.2) and
agree with other reports, indicating that 5-FU treatment
should be avoided in patients with dMMR tumours
[18,19]. Of note, in our case study, 75% of dMMR patients
who developed a recurrence were treated with 5-FU adju-
vant therapy. A possible antitumor immune response by
the lymphocytic infiltrate characteristic of dMMR
tumours [3,19], which may be abrogated by the immuno-
suppressive effects of chemotherapy, could explain these
findings. The favourable prognosis of patients with dMMR
cancers and their lack of benefit from 5-FU therapy
supports a non-adjuvant treatment approach in these
patients, whereas pMMR could be considered as a risk
factor to recommend adjuvant chemotherapy [19].
Cancers with a proficient MMR system, however, com-
prise the majority (80% to 85%) of colorectal cancers and
adjuvant therapy decision in such patients should be
addressed to other factors [19], for instance TYMS
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http://www.biomedcentral.com/1471-230X/13/36expression, which we found associated to therapy benefit
in patients with pMMR tumours (Figure 5).
Different studies reported that CIMP tumours have a
distinct clinical, pathological, and molecular profile [3].
Our results confirm the associations between CIMP and
proximal location, poor tumour differentiation and
MMR deficiency, also showing the recently reported as-
sociation between CIMP-low and male sex [5]. On the
other hand, studies on CIMP phenotype and survival in
colon cancer have yielded somewhat contrasting results
[21,22,49]. Our findings of good prognosis and therapy
benefit in CIMP-High tumours are in agreement with
other reports [22,49], even though other studies
suggested a lack of benefit from 5-FU adjuvant therapy
in these patients [21]. Evidence was also supplied about
an interplay between CIMP and MMR status in affecting
prognosis [50,51]. Unfortunately the absolute number of
dMMR and CIMP-High occurrences are modest in our
case study, therefore conclusive results cannot be drawn
for the latter consideration. The comparison between
our results and the other studies is also complicated by
the fact that some studies considered only stage III
patients [49], while in others the impact of adjuvant 5-
FU chemotherapy relative to the CIMP status was not
addressed in specific subgroups (stage II versus stage III
patients) [21]. A possible explanation for the apparent
chemosensitivity of CIMP-High tumours could be
related to the link between CIMP-High and intracellular
folate methabolism. It has been reported that CIMP-
High tumours show elevated concentrations of intracel-
lular folates, which have a critical importance in deter-
mining the response to 5-FU [52]. Moreover, results
from microarray analysis have revealed that several
genes involved in the pathways of nucleotide metabol-
ism, as well as folate and glutamine metabolism are dif-
ferentially expressed between CIMP-positive and CIMP-
negative tumours [53]. Of note, the reported study also
shows that TYMS levels are significantly higher in
CIMP-positive tumours with respect to CIMP-negative
ones, confirming our results [53]. We also found higher
TYMS levels in patients with a defect in the MMR sys-
tem, in agreement with Ricciardiello et al. [54]. We rec-
ognise that the relationship between TYMS, MMR, and
CIMP in colon cancer could be complex. In our cohort,
50% of CIMP-High tumours showed a defect in the
MMR system and 72% of dMMR tumours exhibited a
high TYMS level. High TYMS levels were more common
also in patients with the CpG island methylator pheno-
type, but while TYMS expression and CIMP-High status
have been associated to a positive outcome in patients
treated with 5-FU, dMMR has been linked to worse out-
come, highlighting the complexity of these molecular
relationships. Stratification of patients according to
combinations of TYMS expression, MMR and CIMPstatuses to assess their joint effect on patient outcome
was not performed in this study because of the small
number of patients. Larger case-studies will be necessary
to deepen investigation on the prognostic and predictive
role of such markers in patients with stage II colon
cancers, also adopting a multisegmental approach to
bowel subsites [55] in order to improve tailored prevent-
ive and therapeutic strategies.
Conclusions
To conclude, this study supports the contention that
TYMS expression (at the mRNA level), dMMR and
CIMP-High status are clinically relevant markers in
patients with sporadic stage II colon cancer being
considered for fluoropyrimidine-based adjuvant therapy.
In particular, this study suggests that patients with high
TYMS levels and CIMP-High status may derive benefit
from adjuvant therapy, which however should be
avoided in those showing dMMR and low TYMS
tumours. Nevertheless the limited sample size of this
study prevents definite conclusions. Further studies with
higher power in sample sizes will be needed to deeply
investigate the roles of TYMS expression, dMMR and
CIMP status in patients with stage II colon cancer.
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